Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 129 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Bovine Thrombin Clear all

Conditions: Effect of Test Articles on the Healing of a Wound Artificially Induced by Liquid Nitrogen Spray
Interventions: Fibrin, White Petrolatum; Biological · Other
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Blood Loss
Interventions: Hemostatic Matrix; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: Not listed
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Stroke, Secondary Prevention
Interventions: optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 5,390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 110
States / cities: Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more

Conditions: Postoperative Pain
Interventions: Bupivacaine, Lidocaine, Thrombin, Tranexamic acid, Aminocaproic acid; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Air Leak From Lung
Interventions: Polyglycolic acid felt, Standard of care; Device · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Abdominoplasty
Interventions: HEMOBLAST Bellows; Device
Lead sponsor: Biom'Up France SAS; Industry
Eligibility: Not listed
Timeline: 2018
U.S. locations: 1
States / cities: Huntsville, North Carolina

Conditions: Parenchymous Tissue Surgical Bleeding
Interventions: Fibrin Sealant Grifols, Surgicel®; Biological · Device
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: Not listed
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 26
States / cities: Loma Linda, California • Los Angeles, California • New Haven, Connecticut + 21 more

Conditions: Sepsis, Disseminated Intravascular Coagulation
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Vascular Surgical Bleeding
Interventions: Fibrin Sealant Grifols, Manual Compression; Biological · Procedure
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: Not listed
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 27
States / cities: Florence, Alabama • Palo Alto, California • San Diego, California + 23 more

Conditions: Coronary Artery Disease
Interventions: Iodixanol, Ioxaglate, Bivalirudin; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Peripheral Vascular Disease
Interventions: Gelfoam/Thrombin, VascuSeal; Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Osteoarthritis
Interventions: Evicel fibrin sealant; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 20 Years to 90 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Vascular Disease
Interventions: ArterX Surgical Sealant, Gelfoam and Thrombin; Device
Lead sponsor: Tenaxis Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Surgical Bleeding
Interventions: HEMOBLAST™ Bellows, absorbable gelatin sponge with thrombin; Device
Lead sponsor: Dilon Technologies Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Carmel, Indiana • Baltimore, Maryland + 2 more

Conditions: Knee Replacement Surgery, Osteoarthritis
Interventions: Standard of Care, FLOSEAL Hemostatic Matrix + Standard of care; Procedure · Drug
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 12
States / cities: Los Angeles, California • Redwood City, California • Englewood, Colorado + 8 more

Conditions: Burns, Skin Graft Complications
Interventions: Tranexamic acid, Thrombin JMI, skin graft; Drug · Procedure
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Facial Rhytidectomy (Face-lift)
Interventions: Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4); Biological
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 6
States / cities: Beverly Hills, California • Los Angeles, California • Atlanta, Georgia + 3 more

Conditions: Muscle Weakness, Pain, Postoperative, Paresthesia, Pain, Muscle
Interventions: Depo-Medrol, Gel-Flow NT; Drug
Lead sponsor: Hardeep Singh; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Heparin-Induced Thrombocytopenia, Thrombosis
Interventions: bivalirudin; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Mild or Moderate Surgical Bleeding
Interventions: Fibrocaps, Gelatin sponge; Biological
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 721 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more

Conditions: Peripheral Vascular Disease, Peripheral Artery Disease, Carotid Stenosis, Aortic Aneurysm, Abdominal, Aortic Aneurysm, Thoracic, Amputation, Wound, Embolism and Thrombosis, Aortic Aneurysm
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: New York, New York

Conditions: Acute Ischemic Stroke
Interventions: Argatroban, Eptifibatide, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 61
States / cities: Birmingham, Alabama • Fullerton, California • La Jolla, California + 47 more

Conditions: Venous Thromboembolism
Interventions: dabigatran etexilate 150 mg twice daily (BID), matching placebo twice daily (BID); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 21
States / cities: Birmingham, Alabama • Huntsville, Alabama • Laguna Hills, California + 17 more

Conditions: Heart Failure, Cardiogenic Shock, Congenital Heart Disease, Cardiomyopathies
Interventions: Cardiohelp device (VA-ECMO), Heparin, Bivalirudin; Device · Drug
Lead sponsor: Stanford University; Other
Eligibility: 0 Years to 16 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Palo Alto, California • New York, New York • Durham, North Carolina + 2 more

Search by objective public record fields.

Study to Determine if Fibrin Affects the Ability of a Wound to Heal

The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation

Pneumostasis With Use of Bio-absorbable Mesh and Fibrin Sealant in Lung Resection

Registry Study for the Use of HEMOBLAST™ Bellows in Abdominoplasty

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries

Thrombin Generation and Thromboelastography in Non-overt DIC

Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery

Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography

Study to Evaluate Safety & Effectiveness of Vascular Sealant System

The Use of Evicel to Reduce Blood Loss in Total Knee Replacement Surgery

ArterX Surgical Sealant, A Randomized Prospective Multicenter Trial

Evaluation of Safety of HEMOBLAST Bellows in Spine Surgery

Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty

Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft

Efficacy and Safety Study of Fibrin Sealant With 4 IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated (FS VH S/D 4) in Face-Lift Procedures

Depo-Medrol on Psoas After LLIF

Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)

A Study of Fibrocaps™ in Surgical Bleeding

Platelet Activity in Vascular Surgery for Thrombosis and Bleeding

Multi-arm Optimization of Stroke Thrombolysis

Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE

Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System